

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 APRIL 2013
ERRATA

(1) This Erratum corrects the entries in the 1 April 2013 Schedule of Pharmaceutical Benefits for Lamivudine + Zidovudine. The listing of 'Lamivudine 150mg + Zidovudine 300mg Alphapharm' brand of items 6234D and 5775Y did not proceed for 1 April 2013. The entries for Lamivudine + Zidovudine in the Highly Specialised Drugs Program section of the Schedule should appear as follows:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Brand Name	Manufacturer
	LAMIVUDINE + ZIDOVUDINE <u>Authority required</u> Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease <u>Authority required</u> Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection						
6234D	lamivudine 150 mg + zidovudine 300 mg tablet, 60	2	5	..	*1113.48	Combivir	VI

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Brand Name	Manufacturer
	LAMIVUDINE + ZIDOVUDINE <u>Authority required (STREAMLINED)</u> 3588 Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease <u>Authority required (STREAMLINED)</u> 3589 Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection						
5775Y	lamivudine 150 mg + zidovudine 300 mg tablet, 60	2	5	..	*1066.96	Combivir	VI

(2) This Erratum corrects the brand names as displayed in the 1 April 2013 Schedule for certain brands *only* of **Irbesartan + Hydrochlorothiazide** for items 8404H, 8405J and 2136K. The brands as displayed in the Schedule and the corrected names are shown below:

		<i>Brands as displayed:</i>	<i>Brands as corrected:</i>
8404H	irbesartan 150 mg + hydrochlorothiazide 12.5 mg tablet, 30	^a Irbesartan HCT Winthrop ^a Irbesartan HCTZ-GA ^a Irbesartan/HCTZ RBX 150/12.5	^a Irbesartan HCT Winthrop 150/12.5 ^a Irbesartan HCTZ-GA 150/12.5 ^a Irbesartan/HCTZ RBX 150/12.5
8405J	irbesartan 300 mg + hydrochlorothiazide 12.5 mg tablet, 30	^a Irbesartan HCT Winthrop ^a Irbesartan HCTZ-GA	^a Irbesartan HCT Winthrop 300/12.5 ^a Irbesartan HCTZ-GA 300/12.5
2136K	irbesartan 300 mg + hydrochlorothiazide 25 mg tablet, 30	^a Irbesartan HCT Winthrop ^a Irbesartan HCTZ-GA	^a Irbesartan HCT Winthrop 300/25 ^a Irbesartan HCTZ-GA 300/25

(3) This Erratum corrects the entry in the 1 April 2013 Schedule for Nicorette and Nicabate P nicotine transdermal patches (item codes 9198D and 5465P). The Schedule entry should appear as shown below:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
	<p>NICOTINE <u>Authority required</u> Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy</p> <p><u>Note</u> Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised. Benefit is improved if used in conjunction with a comprehensive support and counselling program.</p> <p><u>Authority required</u> Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program. Details of the program must be specified in the initial authority application</p> <p><u>Note</u> A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.</p> <p><u>Authority required</u> Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested. Details of the program must be specified in the initial authority application</p> <p><u>Note</u> A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.</p>							
9198D NP	NICOTINE Transdermal patch releasing approximately 15 mg per 16 hours, 28	1	2	..	55.32	36.10	Nicorette Patch	JT
5465P NP	nicotine 21 mg/24 hours patch, 28	1	2	..	55.32	36.10	Nicabate P	GC

(4) This Erratum corrects the entry in the 1 April 2013 Schedule for Olanzapine.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(5) This Erratum corrects the entry in the 1 April 2013 Schedule for Tocilizumab.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.

(6) This Erratum advises corrections to *prices only* published in the April 2013 Schedule of Pharmaceutical Benefits for the items listed below:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
8497F NP	RIVASTIGMINE Rivastigmine 1.5 mg capsule, 56	1	5	..	95.94	36.10	Exelon	NV
8498G NP	Rivastigmine 3 mg capsule, 56	1	5	..	95.94	36.10	Exelon	NV
8499H NP	Rivastigmine 4.5 mg capsule, 56	1	5	..	95.94	36.10	Exelon	NV
8500J NP	Rivastigmine 6 mg capsule, 56	1	5	..	95.94	36.10	Exelon	NV
8563Q NP	Rivastigmine 2 mg/mL oral liquid, 120 mL	1	5	..	95.94	36.10	Exelon	NV
9161E NP	Rivastigmine 4.6 mg/24 hours patch, 30	1	5	..	102.32	36.10	Exelon Patch 5	NV
9162F NP	Rivastigmine 9.5 mg/24 hours patch, 30	1	5	..	102.32	36.10	Exelon Patch 10	NV

No.	PBS Item Number	Listed Drug and Form	Brand	Manufacturer	Pack size	Max Qty	Ex-	Price to	Dispensed	Maximum Safety Net
							Manufacture	Pharmacist	Price	
							1 Apr 13	1 Apr 13	Maximum	
1	8497F	Rivastigmine Capsule 1.5 mg (as hydrogen tartrate)	Exelon	NV	56	56	\$75.60	\$81.29	\$95.94	\$36.10
2	8498G	Rivastigmine Capsule 3 mg (as hydrogen tartrate)	Exelon	NV	56	56	\$75.60	\$81.29	\$95.94	\$36.10
3	8499H	Rivastigmine Capsule 4.5 mg (as hydrogen tartrate)	Exelon	NV	56	56	\$75.60	\$81.29	\$95.94	\$36.10
4	8500J	Rivastigmine Capsule 6 mg (as hydrogen tartrate)	Exelon	NV	56	56	\$75.60	\$81.29	\$95.94	\$36.10
5	8563Q	Rivastigmine Oral solution 2 mg (as hydrogen tartrate) per mL, 120 mL	Exelon	NV	1	1	\$75.60	\$81.29	\$95.94	\$36.10
6	9161E	Rivastigmine Transdermal patch 9 mg	Exelon Patch 5	NV	30	30	\$81.00	\$87.09	\$102.32	\$36.10
7	9162F	Rivastigmine Transdermal patch 18 mg	Exelon Patch 10	NV	30	30	\$81.00	\$87.09	\$102.32	\$36.10